Reference
Reference TypeLiterature
TitleCell-Traversal Protein for Ookinetes and Sporozoites: Naturally Acquired Humoral Immune Response and B-Cell Epitope Mapping in Brazilian Amazon Inhabitants.
AuthorsRodrigo Nunes Rodrigues-da-Silva; Isabela Ferreira Soares; Cesar Lopez-Camacho; João Hermínio Martins da Silva; Daiana de Souza Perce-da-Silva; Antônio Têva; Antônia Maria Ramos Franco; Francimeire Gomes Pinheiro; Lana Bitencourt Chaves; Lilian Rose Pratt-Riccio; Arturo Reyes-Sandoval; Dalma Maria Banic; Josué da Costa Lima-Junior
AffiliationsLaboratory of Immunoparasitology, Oswaldo Cruz Institute, Fiocruz , Rio de Janeiro , Brazil; Nuffield Department of Medicine, The Jenner Institute, The Henry Wellcome Building for Molecular Physiology, University of Oxford , Oxford , UK; Computational Modeling Group, Fiocruz , Fortaleza , Brazil; Laboratory of Clinical Immunology, Oswaldo Cruz Institute, Fiocruz , Rio de Janeiro , Brazil; Laboratory of Immunodiagnostics, Department of Biological Sciences, National School of Public Health, Fiocruz , Rio de Janeiro , Brazil; Laboratory of Leishmaniasis and Chagas Disease, National Institute of Amazonian Research , Manaus , Brazil; Laboratory of Malaria Research, Oswaldo Cruz Institute, Fiocruz , Rio de Janeiro , Brazil.
JournalFront Immunol
Year2017
AbstractThe cell-traversal protein for ookinetes and sporozoites (CelTOS), a highly conserved antigen involved in sporozoite motility, plays an important role in the traversal of host cells during the preerythrocytic stage of species. Recently, it has been considered an alternative target when designing novel antimalarial vaccines against . However, the potential of CelTOS as a vaccine target is yet to be explored. This study evaluated the naturally acquired immune response against a recombinant CelTOS (PvCelTOS) (IgG and IgG subclass) in 528 individuals from Brazilian Amazon, as well as the screening of B-cell epitopes and peptide assays to associate the breadth of antibody responses of those individuals with exposition and/or protection correlates. We show that PvCelTOS is naturally immunogenic in Amazon inhabitants with 94 individuals (17.8%) showing specific IgG antibodies against the recombinant protein. Among responders, the IgG reactivity indexes (RIs) presented a direct correlation with the number of previous malaria episodes ( = 0.003;  = 0.315) and inverse correlation with the time elapsed from the last malaria episode ( = 0.031;  = -0.258). Interestingly, high responders to PvCelTOS (RI > 2) presented higher number of previous malaria episodes, frequency of recent malaria episodes, and ratio of cytophilic/non-cytophilic antibodies than low responders (RI < 2) and non-responders (RI < 1). Moreover, a high prevalence of the cytophilic antibody IgG1 over all other IgG subclasses ( < 0.0001) was observed. B-cell epitope mapping revealed five immunogenic regions in PvCelTOS, but no associations between the specific IgG response to peptides and exposure/protection parameters were found. However, the epitope (PvCelTOS<sub>I136-E143</sub>) was validated as a main linear B-cell epitope, as 92% of IgG responders to PvCelTOS were also responders to this peptide sequence. This study describes for the first time the natural immunogenicity of PvCelTOS in Amazon individuals and identifies immunogenic regions in a full-length protein. The IgG magnitude was mainly composed of cytophilic antibodies (IgG1) and associated with recent malaria episodes. The data presented in this paper add further evidence to consider PvCelTOS as a vaccine candidate.
Curation Last Updated2023-08-18 22:51:52
Epitope
Epitope ID582208
Chemical TypeLinear peptide
Linear SequenceAYFLLGPVVKTLFNK
Source Molecule NamePv cell-traversal protein
Source OrganismPlasmodium vivax (malaria parasite P. vivax)
Starting Position145
Ending Position159
Epitope Reference Details
Epitope Structure DefinesEpitope containing region/antigenic site
Epitope NamePv (145-159)
Location of Data in ReferenceAuthor provided identifier
Immunization
Host OrganismHomo sapiens (human)
Host Details
Host GeolocationBrazil
Age10 to 89 years
1st In Vivo Process
In Vivo Process TypeOccurrence of infectious disease
Disease Statemalaria
Disease StagePost;
1st Immunogen
Epitope RelationTaxonomic Parent
Object TypeOrganism
OrganismPlasmodium
Immunization Comments
Immunization CommentsSera were taken from 32 subjects previously infected with P falciparum, 125 subjects previously infected with P vivax, 158 subjects previously infected with both, and 206 subjects with unknown prior infection with Plasmodium.
B Cell Assay
Qualitative MeasurementPositive-Low
Method/TechniqueELISA
Measurement ofqualitative binding
Measurement Details
Number of Subjects Tested94
Number of Subjects Responded10
Response Frequency (%)10.6
Assayed Antibody
Assayed Antibody Source MaterialSerum
Assayed Antibody Immunoglobulin DomainEntire Antibody
Assayed Antibody Purification StatusPolyclonal
Assayed Antibody Heavy Chain TypeIgG
Antigen
Epitope RelationEpitope
Chemical TypeLinear peptide
Linear SequenceAYFLLGPVVKTLFNK
Source Molecule NamePv cell-traversal protein
Source OrganismPlasmodium vivax (malaria parasite P. vivax)
Starting Position145
Ending Position159
Assay Reference Details
Location of Assay Data in ReferenceFigure 3